A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

NCT01602380 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

462

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone Receptor Positive Breast Cancer

Interventions

DRUG: faslodex 500mg
DRUG: arimidex 1mg
DRUG: faslodex dummy
DRUG: arimidex dummy

Sponsor

AstraZeneca